This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity
Clinical trial NCT06746311 · COMPLETED
Trial details
- NCT number
- NCT06746311
- Sponsor
- Suzhou HepaThera Biotech Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-22
- Primary completion
- 2024-05-13
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.